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doi:10.1016/j.jfma.2011.08.020Background/Purpose: The newly available iron chelator deferasirox (Exjade, Novartis) is ex-
pected to provide better long-term clinical outcomes and improved quality of life for patients
with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral
tablet form.
Methods: We used the Markov model to estimate total additional lifetime costs and quality-
adjusted life years (QALYs) gained with deferasirox versus deferoxamine in patients with
transfusion-dependent thalassemia. Patients were assumed to be 2 years of age at initiation
of chelation therapy. Clinical outcomes in terms of morbidity and mortality from associated
complications and life expectancy for the study population were estimated using the data-
bases of the Bureau of National Health Insurance and the Health and Vital Statistics of Taiwan.
Treatment costs were based on analyses of health insurance claims for patients with
transfusion-dependent thalassemia. Utilities in terms of quality of life were also included
in the model. The incremental costeutility ratio of deferasirox versus deferoxamine was
defined by the ratio of the difference in expected lifetime costs to the difference in QALYs.
One-way sensitivity analyses were performed to examine the robustness of the results to
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222 W.-L. Ho et al.Results: Patients treated with deferasirox are expected to experience a lower incidence of
associated complications and obtain 2.3 QALYs (discounted) at an additional lifetime cost of
US$36,291 per patient (US$15,596 per QALY). Sensitivity analyses showed that the unit drug
cost of deferasirox had the greatest impact on the incremental costeutility ratio. In addition,
the incremental costeutility ratio will increase by delaying the starting age (2 years of age in
our study) of chelation therapy.
Conclusion: Compared with infusional deferoxamine, oral deferasirox improved clinical
outcomes and quality of life in terms of iron chelation in transfusion-dependent patients with
thalassemia at a reasonable cost from a healthcare perspective.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Thalassemia has a very wide clinical range of severity from
transfusion dependency beginning in infancy to a mild
condition requiring little if any medical intervention.
Thalassemia major is the severe form of the disease, pre-
senting with transfusion-dependent anemia, generally in
the first year of life. The mainstay of supportive treatment
is regular blood transfusions accompanied by iron-chelating
therapy.1
With multiple transfusions, excess iron appears in the
plasma that surpasses the capability of the body to safely
store and handle it. Excess iron can potentially penetrate
cells in the liver, heart, endocrine glands, and other organs
and cause progressive tissue damage by generating hydroxyl
free radicals, which cause oxidative stress.2e5 The human
body has a limited capacity to control iron by tight binding of
plasma iron to transferrin, which becomes completely
saturated in patients with an excessive iron load. As
a consequence, non-transferrin-bound iron, including labile
plasma iron, is generated, and free radical formation is
accelerated in several organs and tissues. Iron overload is
frequently associated with transfusion therapy in patients
with thalassemia major,2,6 myelodysplastic syndromes,7 and
sickle cell disease.8 If untreated, accumulation of iron in
various organs may result in certain fatal complications,
including cardiac dysfunction, diabetes, liver disease,
hypogonadism, hypothyroidism, and hypoparathyroidism.
Other than transferrin, the human body itself has no
physiological mechanism for removing excess iron. There-
fore, iron chelation therapy is currently the only means of
managing iron overload in transfusion-dependent patients.
Deferoxamine has been the standard therapeutic option for
thalassemia for the past 40 years. This drug effectively
maintains iron stores at levels that are normal to near-
normal, reduces organ damage, and increases life expec-
tancy in patients with thalassemia.9 However, the poor
bioavailability and short plasma elimination half-life of
deferoxamine require that it be administered as a subcu-
taneous or intravenous infusion over a period of 8e12 hours
five to seven times per week. Therefore, patient compli-
ance is suboptimal because of the discomfort and demands
associated with the administration regimen.10,11
Deferiprone is an orally absorbed iron chelator first
licensed in India, followed by the European Union and other
countries outside the United States and Canada, including
many countries in Asia in the late 1990s. The eliminationhalf-life of deferiprone is 2e3 hours in most patients, and
therefore it is given at a dose of 25 mg/kg body weight
three times a day for a total daily dose of 75 mg/kg body
weight. By combining deferiprone with deferoxamine, an
increased proportion of patients may achieve iron balance
and improved myocardial iron removal when compared
with monotherapy with either drug.12e17
However, several adverse and potentially severe events
associated with deferiprone, including agranulocytosis
[absolute neutrophil count (ANC)< 500/mm3], neutropenia
(ANC< 1500/mm3), and arthropathy, may have limited its
use in routine clinical practice.18,19 Because of this, only
a limited number of patients with transfusion-dependent
thalassemia in Taiwan were on the deferiprone regimen
before the introduction of deferasirox, partly due to its
special application to the Bureau of National Health Insur-
ance (BNHI) and unwanted adverse effects.
Deferasirox, a newer oral iron chelator, was approved by
theUS Food andDrugAdministration inOctober 2005 for first-
line use in adults and children (age 2 years) with chronic
iron overload that is due to blood transfusions.20 It has now
been approved in most Asian countries, including Malaysia,
Singapore, Taiwan, and Thailand.2 This drug is orally
bioavailable, and its terminal eliminationhalf-life is between
8 and 16 hours, allowing once-daily administration.21
In Taiwan, deferoxamine has been the mainstay of iron
chelation therapy for patients with transfusion-dependent
thalassemia since its introduction in the 1960s. With the
approval of deferasirox in many countries worldwide,
including Taiwan in the 2000s, some issues have appeared
regarding differences in compliance and quality of life
associated with oral (deferasirox) versus infusional (defer-
oxamine) therapy. A higher acquisition cost of deferasirox is
anticipated because of potentially better drug compliance,
with the trade-off of reduced costs for infusional therapy
and for the treatment of complications of iron overload in
patients with poorly controlled thalassemia.
Therefore, from a healthcare system perspective, the
aim of this study was to evaluate the costeutility of
deferasirox versus deferoxamine in patients with
transfusion-dependent thalassemia given the similar
treatment efficacy and safety of deferasirox and deferox-
amine.22,23 We assumed that patients with transfusion-
dependent thalassemia started iron chelation therapy at
the age of 2 years. Therefore, the objective of this study
was to compare lifetime clinical outcomes and economic
impacts between deferoxamine and deferasirox for
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thalassemia using a simulation modeling method.Methods
Overview
The subjects of economic evaluation in this study, defer-
oxamine and deferasirox, have comparable treatment effi-
cacies for reducing the incidence of iron overload-related
complications in patients with transfusion-dependent thal-
assemia. Because of different administration methods, the
once-daily oral form of deferasirox is, however, expected to
have better drug compliance than the subcutaneous or
intravenous form of deferoxamine. Therefore, patients
treated with deferasirox are expected to show a lower
incidence of complications than those treated with
deferoxamine.
In addition to the potential benefits described above,
deferasirox is also, because of its oral form, expected to
provide a better quality of life for patients than treatment
with deferoxamine. Therefore, after adjusting for quality-
of-life parameters, patients treated with deferasirox are
still expected to show better quality-adjusted life years
(QALYs) than those treated with deferoxamine.
With cost and outcome indicators available, a simple
costeutility ratio can be calculated for both chelation
therapies, and a comparison can be made. In this study, the
costeutility ratio was calculated by dividing total treat-
ment costs by total QALYs gained, with both costs and life
years discounted.
Although several long-term benefits are anticipated with
using deferasirox as a chelation agent, the unit cost of the
newly introduced deferasirox is much higher than that of
deferoxamine. To provide a full spectrum of information to
decision-makers, it is better to have an indicator that
incorporates the various parameters presented above.
Based on the above statements, this study of economic
evaluation intended to answer the question: “How much
does it cost to obtain an additional QALY for patients with
transfusion-dependent thalassemia using deferasirox?”Study design
To answer this study question, a pharmaco-economic
approach was adopted. Specifically, the study design was
categorized as a “costeutility analysis”.24 For the proposed
study, a simulation modeling method was used to project
lifetime outcomes and costs for the population of interest
while incorporating quality-of-life parameters.Study population and assumptions
The study population was defined as patients who had
a primary diagnosis of thalassemia [International Classifi-
cation of Diseases, 9th revision (ICD-9) code 282.4] and who
received regular blood transfusions (and who therefore had
a certification of catastrophic illness and chronic disease)
according to the claims database of the BNHI of Taiwan. Itwas assumed that patients started iron chelation therapy at
the age of 2 years.
Study model and parameters used in the model
For chronic or complex diseases, it is best to incorporate
a decision analysis model into the analysis that allows
researchers to incorporate changes in health states over
time. The Markov model is a decision analysis model that
enables researchers to track changes in the quality of life,
the quantity of life, and the medical cost of a disease over
time when different health interventions are applied.24,25
In the Markov model, each patient in a hypothetical
cohort is essentially treated as an individual. Each patient
can be assigned different characteristics and risk factors at
the beginning. As patients age, the model records the
changes in their health status. When a patient develops
a medical event (e.g., iron overload-related cardiac disease
or diabetes mellitus), any associated costs incurred and any
change in health-related quality of life will be captured in
the Markov model. Therefore, the Markov model is
a powerful and accurate way of modeling the change in
health states over time.
In this study, we used a Markov model that assigned
various risk factors such as the type of iron chelation
therapy, treatment compliance, and probabilities of asso-
ciated complications to each individual of a hypothetical
study population. The model then calculated clinical
outcomes in terms of morbidity and mortality from associ-
ated complications and expected life expectancy for the
study population.
We also added parameters of treatment costs and utility
regarding quality of life to the model. In addition, by taking
quality-of-life parameters into consideration, the life
expectancies provided earlier were transformed to QALYs
gained. QALYs are a measure of health outcome that
adjusts life years for the quality of life during those years
and provides a common unit for comparing health benefits
across different diseases and/or interventions. QALYs are
calculated by multiplying life years by utility values. Utility
values are weights that represent preferences for different
health states and range from 0.0 (death) to 1.0 (perfect
health).24
Finally, the study model provided a measure of the
incremental costeutility ratio of the two medications. The
incremental costeutility ratio of deferasirox versus defer-
oxamine was defined as the ratio of the difference
(deferasirox minus deferoxamine) in expected lifetime
costs to the difference (deferasirox minus deferoxamine) in
QALYs.
Drug cost parameters
The unit costs per milligram were US$0.02 for deferoxamine
and US$0.0607 for deferasirox. Prescribed dosages of
deferasirox and deferoxamine were estimated to be
24.6 mg/kg/d, 7 days per week and 47.4 mg/kg/d, 5 days
per week, respectively.22 In addition, administering
subcutaneous or intravenous infusion of deferoxamine
incurs administration costs, including an infusion or intra-
venous service or infusion supplies (e.g., pumps). It was
224 W.-L. Ho et al.estimated that deferoxamine infusions cost US$141.1 per
month for each patient. In contrast, because of its oral
tablet form, the cost of administering deferasirox was
assumed to be zero.
Treatment cost parameters associated with iron
overload complications
There are five associated complications of iron overload:
cardiac disease, diabetes mellitus, hypothyroidism, hypo-
gonadism, and hypoparathyroidism. Annual treatment costs
for each complication for each patient were required by
the model to calculate the total lifetime treatment costs.
To provide these parameters, we extracted patient data
from the claims database of the BNHI. Data for the study
population were collected from both the inpatient data-
base from 1997 to 1999 and the outpatient database from
2000 to 2004. The data were identified by diagnostic codes
for (1) cardiac disease, including cardiomyopathy (ICD-9
code 425.4), conduction disorders (ICD-9 code 426.10),
cardiac dysrhythmias (ICD-9 code 427.9), and heart failure
(ICD-9 code 428.0); (2) diabetes mellitus (ICD-9 code
250.00); (3) hypothyroidism (ICD-9 code 244.9); (4) hypo-
gonadism (ICD-9 code 256.3 or 257.2); and (5) hypopara-
thyroidism (ICD-9 code 252.1). The treatment costs
associated with each complication for each patient were
calculated to obtain the annual average cost of each
complication.
Compliance
Compliance with deferoxamine, which was estimated to be
50% in Taiwan, was derived from prior clinical data at
National Taiwan University Hospital.26 Because there has
been no clinical experience with using deferasirox in
Taiwan, we estimated the improvement in compliance
based on data from a nonrandomized prospective study
comparing the thrice-daily oral chelator deferiprone with
deferoxamine.27 Therefore, we conservatively estimated
that the once-daily oral chelator deferasirox would improve
compliance by 16% versus deferoxamine. Because of this
assumption, we carried out a sensitivity analysis for this
parameter.
Public health parameters
Because the dosage for each patient was determined by his
or her weight, average weight by age was obtained from the
National Survey of Nutrition and Vital Statistics conducted
in Taiwan from 2001 to 2004. The model assumed that the
probability of complications for the study population with
perfect drug compliance would be the same as that for the
general population, and that a lack of drug compliance
would cause complications.
There were no data available in the public domain
regarding the age-matched morbidity rate of these associ-
ated complications in Taiwan. Therefore, to obtain those
figures, the database provided by the BNHI was used. The
age-matched incidence rate of iron overload-related
complications for the study population was obtained from
the database.In addition to morbidity, the study model also required
the mortality rate after developing each complication to
simulate the number of life years remaining. For that
purpose, the age-matched mortality rate of each associ-
ated complication was retrieved from the database of the
Health and Vital Statistics in Taiwan for the year 2004.
Other parameters and assumptions
Quality parameters are important in a costeutility study
that requires adjustment for indicators (e.g., life years).
Because deferasirox is administered in an oral form, there
is no deterioration in the quality of life. In contrast,
because deferoxamine is administered by injection, it is
estimated that the quality of life for patients treated with
deferoxamine is 28% less than that for patients who
received deferasirox.21
For patients with cardiac disease, their quality of life is
estimated to be approximately 15% less than that for indi-
viduals without cardiac disease.21,28 For patients suffering
from other complications, the quality of life is estimated
to be 5% less than that for individuals without such
complications.24
In addition to the parameters described above, some
important assumptions were adopted for this study model.
The model assumed that individuals in the study population
started iron chelation therapy at the age of 2 years and
continued for their lifetime. In addition, both life years and
costs were subject to an annual discount rate of 3%.30
Analysis plan
After obtaining the values for the parameters presented
above, base-case analyses were then performed. The
Markov model, which was calculated using the macro
function of Microsoft Excel (Microsoft Corporation, Red-
mond, WA, USA), generates results of expected life years,
QALYs, and expected medical costs regarding chelation
therapy [drug and administration (deferoxamine only)] and
iron overload-related complications in the study population
for the two scenarios (treated with deferoxamine or with
deferasirox). To obtain a complete picture of the simula-
tion model, various one-way sensitivity analyses were also
conducted by assigning the range of important parameters
of the Markov model. Results from the sensitivity analyses
can add to the information base on which policy is made by
health authorities or clinicians.
Results
Costs of treatment for iron overload-related
complications
Both outpatient data from 2000 to 2004 and inpatient data
from 1997 to 1999 that were extracted from the BNHI
database were used to calculate the treatment costs of iron
overload-related complications. Using the diagnostic code
ICD-9-CM as the identifier, the medical records of patients
with transfusion-dependent thalassemia were identified
from the database. The numbers of patients with
Table 1 Number of patients with iron overload-related
complications and their visits to a healthcare provider.
Year Number
of patients
Number
of visits
Yearly average frequency
of visits (no. of visits/
no. of patients)
Outpatient visits
2000 723 7462 10.32
2001 801 8642 10.79
2002 941 10,193 10.83
2003 1107 12,251 11.07
2004 1189 14,763 12.42
Inpatient visits
1997 265 473 1.78
1998 292 512 1.75
1999 364 683 1.88
Pharmaco-economic evaluation of deferasirox 225complications and related visits to a healthcare provider
each year are shown in Table 1.
There were increasing numbers of patients with
transfusion-dependent thalassemia whose medical costs
had been reimbursed by BNHI during the data years avail-
able (Table 1). In addition, we observed that the yearly
average frequency of outpatient visits increased from 10.32
times per patient to 12.42 times per patient from 2000 to
2004; however, the frequency of inpatient visits seemed
relatively stable from 1997 to 1999 (Table 1).
We examined five major iron overload-related compli-
cations in the study population. The data were identified by
the diagnostic codes for (1) cardiomyopathy, conduction
disorders, cardiac dysrhythmias, or heart failure; (2) dia-
betes mellitus; (3) hypothyroidism; (4) hypogonadism; and
(5) hypoparathyroidism. An analysis of visit and patient
numbers corresponding to the individual complication for
each data year is presented in Table 2. Cardiac disease and
diabetes mellitus were the most common complications in
the study population, and they were the most common
causes of outpatient and inpatient visits during the data
years. Hypogonadism, hypothyroidism, and hypoparathy-
roidism accounted for fewer outpatient and inpatient visits.
Of note, few patients sought medical attention asTable 2 Outpatient visits from 2000 to 2004 and inpatient visit
Year Number of visits (patients) by ind
Cardiac disease Diabetes mellitus Hyp
Outpatient visits
2000 245 (32) 268 (40) 88
2001 358 (49) 328 (46) 142
2002 359 (51) 476 (53) 115
2003 415 (65) 517 (60) 171
2004 558 (67) 678 (66) 128
Inpatient visits
1997 44 (35) 49 (40) 3 (2
1998 43 (35) 40 (30) 4 (2
1999 69 (31) 33 (30) 4 (4outpatients for hypoparathyroidism, and no patients were
hospitalized for hypoparathyroidism.
Because each record from the database represents an
outpatient or inpatient visit, the total amount paid is shown
in each record and indicates the amount that the BNHI
reimbursed to the healthcare provider for medical services.
By using the diagnostic code ICD-9-CM as the identifier, the
medical records of patients with iron overload-related
complications were identified and extracted from the
database, and the yearly average treatment costs were
calculated. However, because the patient numbers for
individual complications were different in each data year,
the yearly average treatment costs needed to be weighted
by the number of patients each year in order to arrive at
a weighted average treatment cost for outpatient and
inpatient services.
Table 3 shows that the weighted yearly outpatient
average costs for treating the iron overload-related
complications of diabetes mellitus were US$1476, fol-
lowed by US$1188 for cardiac disease, US$975 for hypo-
thyroidism, US$605 for hypogonadism, and US$293 for
hypoparathyroidism. The weighted yearly inpatient
average costs for treating the iron overload-related
complications of cardiac disease were US$978, followed
by US$594 for diabetes mellitus, US$408 for hypogonadism,
and US$259 for hypothyroidism. No patients were hospi-
talized for hypoparathyroidism.
The yearly average treatment costs for each complication
were calculated by combining the weighted average treat-
ment costs of both outpatient and inpatient services. The
yearly average treatment costs for iron overload-related
cardiac disease were US$2166, followed by US$2070 for dia-
betes mellitus, US$1234 for hypothyroidism, US$1013 for
hypogonadism, and US$293 for hypoparathyroidism. These
results were incorporated into the study model.
Base-case analyses
After entering all the required parameters onto the work-
sheet of the study model, base-case analyses were per-
formed. The major results of the base-case analyses are
shown in Table 4. Over the 50-year time frame of the
model, the model predicted that patients treated withs from 1997 to 1999 for iron overload-related complications.
ividual iron overload-related complications
ogonadism Hypoparathyroidism Hypothyroidism
(15) 10 (2) 149 (20)
(16) 11 (3) 151 (16)
(18) 13 (2) 155 (18)
(35) 18 (6) 157 (26)
(21) 8 (5) 170 (22)
) 0 8 (7)
) 0 5 (4)
) 0 6 (6)
Table 3 Outpatient and inpatient costs for individual iron overload-related complications.
Year Medical costs by individual iron overload-related complications (US$)
Cardiac disease Diabetes mellitus Hypogonadism Hypoparathyroidism Hypothyroidism
Outpatient visits
2000 962 1378 503 343 773
2001 1251 1590 456 216 1449
2002 949 1557 643 202 1237
2003 957 1282 572 496 719
2004 1653 1566 811 114 905
Weighted average costs 1188 1476 605 293 975
Inpatient visits
1997 1002 653 226 0 252
1998 884 603 674 0 204
1999 1057 506 365 0 304
Weighted average costs 978 594 408 0 259
Average treatment cost 2166 2070 1013 293 1234
226 W.-L. Ho et al.deferasirox would have a lower incidence of iron overload-
related complications, except for hypogonadism, than
patients treated with deferoxamine.
Analysis of the most frequent complications of cardiac
disease and diabetes mellitus showed reductions in the
incidences of diabetes mellitus and cardiac disease of 13.7%
(61.3% vs. 75.0%) and 0.2% (99.2% vs. 99.4%), respectively.Table 4 Results from the base-case analyses.
Base-case item Defer
Complication (% of patients)
Cardiac disease 99.2%
Diabetes mellitus 61.3%
Hypothyroidism 30.0%
Hypogonadism 18.0%
Hypoparathyroidism 8.8%
Causes of death (% of patients)
Cardiac death 99.1%
Death from other causes 0.9%
Cardiac disease-free life years 9.2
Life years
Not discounted 15.3
Discounted 11.9
Quality-adjusted life years
Not discounted 11.7
Discounted 9.2
Costs (US$)
Iron chelator 81,21
Chelation administration 0
Iron overload-related cardiac disease 11,11
Iron overload-related diabetes mellitus 8408
Iron overload-related hypothyroidism 1918
Iron overload-related hypogonadism 491
Iron overload-related hypoparathyroidism 142
Total costs (US$) 103,2
Cost per QALY gained (US$)However, the incidence of hypogonadism in patients
treated with deferasirox was 2.7% more than that in
patients treated with deferoxamine (18.0% vs. 15.3%). Iron
overload-related cardiac disease was the major cause of
death in deferasirox- and deferoxamine-treated patients
(99.1% vs. 99.3%). Time to develop cardiac disease was
projected to be increased by 2.2 years with deferasirox.asirox Deferoxamine Difference
99.4% 0.2%
75.0% 13.7%
30.4% 0.4%
15.3% 2.7%
9.5% 0.7%
99.3% 0.2%
0.7% 0.2%
7.0 2.2
13.2 2.1
10.6 1.3
8.5 3.2
6.9 2.3
9 34,330 46,888
9078 9078
0 11,713 603
9467 1059
1873 45
397 94
138 4
88 66,997 36,291
15,596
Table 5 Sensitivity analysis for the unit cost of defer-
asirox (original valueZ US$0.0607).a
Cost of deferasirox/
mg (US$)
0.04 0.05 0.06 0.07 0.08
Cost/QALY (US$) 3693 9443 15,194 20,944 26,694
a For each change of US$0.01 of deferasirox per milligram,
there was a difference of approximately US$6000 for obtaining
each additional QALY.
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ulation had been treated with deferasirox, each patient
would be expected to gain more life years as well as QALYs
than if they had been treated with deferoxamine. The
model estimated that patients treated with deferasirox
would gain 2.1 additional life years (undiscounted)
compared with those who had been treated with deferox-
amine (15.3 life years vs. 13.2 life years). After adjusting
for quality-of-life parameters, deferasirox yielded 3.2
additional QALYs (undiscounted; 11.7 QALYs vs. 8.5 QALYs).
On a discounted basis, the gains in overall and quality-
adjusted life expectancy with deferasirox versus deferox-
amine were 1.3 life years and 2.3 QALYs.
Because of the better long-term clinical outcomes,
deferasirox would reduce treatment costs over a lifetime
for iron overload-related cardiac disease and diabetes
mellitus by US$603 (US$11,110 vs. US$11,713) and US$1059
(US$8408 vs. US$9467), respectively. Because of higher drug
costs (US$81,219 for deferasirox and US$34,330 for defer-
oxamine) that were partly offset by savings in administra-
tion costs for deferoxamine (US$9078) and, to a lesser
degree, savings in the medical costs arising from the
complications of cardiac disease (US$603) and diabetes
mellitus (US$1059), patients treated with deferasirox would
experience a much higher total lifetime cost than would
those treated with deferoxamine. Therefore, the total
lifetime costs were estimated to be US$103,288 per person
treated with deferasirox versus US$66,997 per person
treated with deferoxamine. The costeutility of deferasirox
versus deferoxamine was therefore estimated to be
US$15,596 per QALY gained.
Sensitivity analyses
There were several parameters that were subject to
change, and therefore these were used in sensitivity anal-
yses. Several one-way sensitivity analyses were performed
using the incremental costeutility ratio as the primary
outcome indicator for this study. Results of sensitivity
analyses showed that when other parameters were held
constant, the total costs for obtaining each additional QALY
by using deferasirox (i.e., the costeutility ratio) wereTable 6 Sensitivity analysis for drug compliance with deferoxa
Compliance with deferoxamine 35% 41%
Cost/QALY (US$) 14,266 14,368
a From 47% of compliance with deferoxamine, for each change of 6%
additional QALY.sensitive to the unit cost of deferasirox (Table 5), the drug
compliance with deferoxamine (Table 6), the drug compli-
ance change from deferoxamine to deferasirox (Table 7),
and the starting age of chelation therapy (Table 8).
Among the four parameters used for sensitivity analyses,
the unit costs of deferasirox showed the most dramatic
influence on the costeutility ratio. For each change of
US$0.01 of deferasirox per milligram, there was a differ-
ence of approximately US$6000 for obtaining each addi-
tional QALY. In comparison, when delaying the starting age
of chelation therapy from 2 years to 5 years, there would be
an increase of US$1383 for obtaining each additional QALY.Discussion
Chelation therapy is the only treatment currently available
for patients suffering from iron overload caused by trans-
fusion. Although the treatment efficacies of the two
currently available iron chelators, deferasirox and defer-
oxamine, were found to be equivalent, deferasirox was
expected, because of its oral tablet form, to provide better
clinical outcomes as a result of improved drug compliance
and eventually better costeutility.
By using a population with thalassemia as the partici-
pants in our investigation, we compared various clinical
outcomes and pharmaco-economic indicators between the
two iron chelators with the aid of a Markov model and data
from the claims database of the BNHI of Taiwan. The model
estimated that the incidences of cardiac disease and dia-
betes, the most common iron overload-related complica-
tions in patients with transfusion-dependent thalassemia,
were reduced by 0.2% and 13.7%, respectively, in patients
treated with deferasirox. The time to development of
cardiac disease was projected to be increased by 2.2 years
with deferasirox. With this model, reduced morbidity and
mortality incidence rates inevitably led to higher life years
as well as QALYs for patients treated with deferasirox.
Because of higher unit drug costs and longer life years,
patients treated with deferasirox are expected to experi-
ence a much higher total lifetime drug cost than would
patients treated with deferoxamine. This prediction leads
to a trade-off, such that the longer life years and better
quality of life come at an increased treatment cost. The
model estimated that treatment with deferasirox would
result in an additional 2.3 QALYs at an additional expected
lifetime cost of US$36,291, yielding a costeutility ratio of
US$15,596 per QALY gained. This value is below the range
that is considered to be acceptable in Taiwan (i.e.,
US$50,000e100,000 per QALY gained).32,33 The Taiwanese
government has conducted a National Screening Program
that began in 1993, and based on these data, the number of
births of patients with thalassemia major has decreasedmine (original valueZ 50%).a
47% 53% 59% 65%
15,027 16,259 17,773 19,412
, there was a difference of more than US$1000 for obtaining each
Table 7 Sensitivity analysis for the drug compliance change from deferoxamine to deferasirox (original valueZ 16%).a
Compliance change 10% 13% 16% 19% 22% 25%
Cost/QALY (US$) 14,914 15,264 15,596 15,917 16,232 16,542
a For each 3% change in compliance change, there was a difference of more than US$300 for obtaining each additional QALY.
228 W.-L. Ho et al.from 20 to 3e6 persons per year as of 2002.28 Assuming that
there are three to six new cases of transfusion-dependent
thalassemia in Taiwan per year, the financial burden of
increased use of deferasirox in this population is small (i.e.,
ranging from US$46,788 to US$93,576).
In addition to the base-case analyses presented above,
four parameters were used to perform sensitivity analyses
against the indicator of incremental costs for obtaining an
additional QALY: the unit cost of deferasirox, the drug
compliance with deferoxamine, the change in drug
compliance with a switch from deferoxamine to defer-
asirox, and the starting age of chelation therapy. The model
found that the unit drug cost of deferasirox has the most
dramatic impact on the incremental costeutility ratio. For
each change of US$0.01 in the price of deferasirox per
milligram, there was a difference of approximately
US$6000 for obtaining each additional QALY. In addition,
starting chelation therapy at an earlier age should result in
a reduced lifetime treatment cost because delaying the
starting age of chelation therapy from 2 years to 5 years is
predicted to result in an increase of US$1383 for obtaining
each additional QALY.Limitations of this study
This study used a decision modeling approach, specifically
the Markov model, to perform the analyses. Because the
results of the base-case analyses are not derived from real-
life experiences but from simulation with the best available
parameters, they can serve only as a guide. To overcome
the drawbacks posed by the decision model, we performed
various sensitivity analyses to provide a full spectrum of
information to decision-makers.
The study population comprised patients with
transfusion-dependent thalassemia who were at high risk
for iron overload. Therefore, the results of this study
cannot be generalized to other populations who also
require chelation therapy, such as patients with myelo-
dysplastic syndrome or other chronic types of anemia.29,31
Also, we estimated the expected improvement in compli-
ance with deferasirox versus deferoxamine to be approxi-
mately 16% based on a previous report27 comparing
compliance with deferiprone with that of deferoxamine.
The estimate may be conservative, as compliance withTable 8 Sensitivity analysis for the starting age of chelation th
Start of chelation therapy (age in years) 1
Cost/QALY (US$) 14,986
a When delaying the starting age of chelation therapy from 2 to 5
additional QALY.a once-daily oral chelator (deferasirox) would be expected
to be better than that with a thrice-daily oral chelator
(deferiprone).
The other limitation of this study is due to the data
source. The BNHI database served as the data source for
parameters of treatment costs. Because the purpose of the
BNHI database is to claim fees from the BNHI to reimburse
healthcare providers, the construction of the database may
not perfectly fit the needs of this study. For example, each
medical record in the database represents one outpatient
or inpatient visit. It is possible that one medical record may
contain more than one diagnostic code. If there were more
than one diagnostic code regarding iron overload-related
complications in one record, it would be difficult to attri-
bute the total costs of the record separately and specifi-
cally to individual complications. Therefore, some values
of the parameters may not reflect the exact medical
condition.
In addition, to collect information about the relevant
parameters, we were granted use of the data in the
nationwide health insurance claims database. During the
time period of our research, however, only data for
outpatient visits from 2000 to 2004 and inpatient visits from
1997 to 1999 were available. Nevertheless, we believe that
the influence of the aforementioned limitations should be
minimal because there has been no significant change in
the treatment strategies for patients with transfusion-
dependent thalassemia in the last 20 years in Taiwan.
In conclusion, deferasirox has been shown to be safe and
effective, similar to deferoxamine, in patients with
transfusion-dependent thalassemia. Because of its method
of administration, deferoxamine provides poor quality of
life for patients and eventually affects long-term clinical
outcomes. The newer iron chelator deferasirox is expected
to overcome those drawbacks because it is in oral tablet
form. The results of this study show that a marked
improvement in drug compliance and a reduction in iron
overload-related complications can be achieved by using
deferasirox. However, because deferasirox has been
licensed for use in Taiwan for fewer than 10 years, the long-
term side effects and efficacy are not completely known
and should be monitored closely.
In addition, expensive new technologies always pose
financial considerations for decision-makers. The model
estimated that treatment with deferasirox will result in anerapy (original valueZ 2).a
2 3 4 5
15,596 16,116 16,568 16,979
years, there would be an increase of US$1383 for obtaining each
Pharmaco-economic evaluation of deferasirox 229additional 2.3 QALYs at an additional expected lifetime cost
of US$36,291, yielding a costeutility ratio of US$15,596
per QALY gained. Therefore, we suggest that, from
a healthcare perspective, deferasirox should be considered
for use in patients who require iron chelation therapy.
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